Andrea S Shin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1093292/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy. Gastroenterology, 2015, 148, 537-546.e4.	1.3	143
2	Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 1270-1275.e1.	4.4	132
3	Systematic review with metaâ€analysis: highly selective 5â€HT4 agonists (prucalopride, velusetrag or) Tj ETQq1 1	0.784314 3.7	rgBT /Over
4	The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2019, 17, 256-274.	4.4	119
5	Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clinical Gastroenterology and Hepatology, 2017, 15, 166-174.	4.4	109
6	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 380-390.e1.	4.4	104
7	The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus. Clinical Gastroenterology and Hepatology, 2013, 11, 1453-1459.e4.	4.4	97
8	Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying. Diabetes Care, 2013, 36, 41-48.	8.6	93
9	Effect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea. American Journal of Gastroenterology, 2014, 109, 1621-1630.	0.4	82
10	Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2016, 7, e173.	2.5	70
11	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clinical Gastroenterology and Hepatology, 2019, 17, 2471-2478.e3.	4.4	65
12	Diagnostic Assessment of Diabetic Gastroparesis. Diabetes, 2013, 62, 2667-2673.	0.6	60
13	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. American Journal of Physiology - Renal Physiology, 2014, 307, G508-G516.	3.4	45
14	Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. Clinical Gastroenterology and Hepatology, 2017, 15, 1844-1854.	4.4	43
15	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. Gastroenterology, 2020, 158, 786-788.e1.	1.3	33
16	Novel association of rectal evacuation disorder and rumination syndrome: Diagnosis, comorbidities, and treatment. United European Gastroenterology Journal, 2014, 2, 38-46.	3.8	32
17	Systematic review and metaâ€analysis: Efficacy of patented probiotic, <scp>VSL</scp> #3, in irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13427.	3.0	27
18	A Randomized Trial of 5-Hydroxytryptamine4–Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. Clinical Gastroenterology and Hepatology, 2015, 13, 701-708.e1.	4.4	25

ANDREA S SHIN

#	Article	IF	CITATIONS
19	Therapeutic Applications of Ghrelin Agonists in the Treatment of Gastroparesis. Current Gastroenterology Reports, 2015, 17, 430.	2.5	19
20	Interpretation of overall colonic transit in defecation disorders in males and females. Neurogastroenterology and Motility, 2013, 25, 502.	3.0	18
21	Lactose Intolerance. Mayo Clinic Proceedings, 2020, 95, 1499-1505.	3.0	18
22	Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis. FEMS Microbiology Letters, 2021, 368, .	1.8	16
23	Characterization of Proximal Small Intestinal Microbiota in Patients With Suspected Small Intestinal Bacterial Overgrowth: A Cross-Sectional Study. Clinical and Translational Gastroenterology, 2019, 10, e00073.	2.5	13
24	Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2020, 19, 1538-1553.e14.	4.4	12
25	Association Between Proteomic Blood Biomarkers and DTI/NODDI Metrics in Adolescent Football Players: A Pilot Study. Frontiers in Neurology, 2020, 11, 581781.	2.4	11
26	High prevalence of food intolerances among US internet users. Public Health Nutrition, 2021, 24, 531-535.	2.2	9
27	Patient considerations in the management of chronic constipation: focus on prucalopride. Patient Preference and Adherence, 2016, Volume 10, 1373-1384.	1.8	8
28	Risk Factors Associated With Upper Aerodigestive Tract or Coliform Bacterial Overgrowth of the Small Intestine in Symptomatic Patients. Journal of Clinical Gastroenterology, 2020, 54, 150-157.	2.2	8
29	Early adverse life events and postâ€traumatic stress disorder in patients with constipation and suspected disordered defecation. Neurogastroenterology and Motility, 2022, 34, e14195.	3.0	8
30	Feeling gutted in chronic kidney disease (CKD): Gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis. Seminars in Dialysis, 2021, , .	1.3	7
31	Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterology, 2019, 6, e000322.	2.7	6
32	The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose. Clinical Gastroenterology and Hepatology, 2022, 20, 508-510.	4.4	6
33	Associations of Food Intolerance with Irritable Bowel Syndrome, Psychological Symptoms, and Quality of Life. Clinical Gastroenterology and Hepatology, 2022, 20, 2121-2131.e3.	4.4	6
34	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 2840-2842.	4.4	5
35	Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2022, 56, 234-242.	2.2	5
36	Introduction of Clinical Practice Update Committee Articles. Clinical Gastroenterology and Hepatology, 2017, 15, 4.	4.4	4

ANDREA S SHIN

#	Article	IF	CITATIONS
37	Delayed Castric Emptying Is Not Associated with a Microbiological Diagnosis of Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2021, 66, 160-166.	2.3	3
38	The changing prevalence of functional constipation: why words matter. The Lancet Gastroenterology and Hepatology, 2021, 6, 600-602.	8.1	3
39	Relationships of Intestinal Lactase and the Small Intestinal Microbiome with Symptoms of Lactose Intolerance and Intake in Adults. Digestive Diseases and Sciences, 2022, 67, 5617-5627.	2.3	2
40	Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 2016, 151, 45.	1.3	0
41	2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers. Journal of Clinical and Translational Science, 2018, 2, 12-13.	0.6	0
42	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 573-574.	4.4	0
43	Refers to: Paul Enck. Not more, but less studies are warranted—lf you take your metaâ€analysis seriously. Neurogastroenterology and Motility, 2019, 31, e13490.	3.0	0
44	Acute Diarrheal Illness. Gastroenterology, 2020, 158, 838-839.	1.3	0
45	COVID-19 Epidemiology and Google Searches. Clinical Gastroenterology and Hepatology, 2021, 19, 406-407.	4.4	0